BIOMAT Database Logo BIOMAT Database Logo

Phase II study of 13-cis-retinoic acid plus interferon-alpha 2a in heavily pretreated squamous carcinoma of the cervix. 1995

A V Hallum, and D S Alberts, and S M Lippman, and L Inclan, and G J Shamdas, and J M Childers, and E A Surwit, and M Modiano, and K D Hatch
Department of Obstetrics-Gynecology, University of Arizona, College of Medicine, Tucson 85724, USA.

The combination of 13-cis-retinoic acid (13-cRA) and interferon (IFN)-alpha 2a has been reported to be highly active in previously untreated squamous carcinoma of the cervix. In this phase II study, 13-cRA was given at a dose of 1 mg/kg/day and IFN-alpha 2a was given subcutaneously at a dose of 3 million units/m2/day. Thirteen of 14 patients enrolled in this study are evaluable for response and toxicity. There were no complete or partial responses. Ten patients had progressive disease and the remaining three had stable disease. Principle toxicities were fatigue, nausea, and vomiting. This regimen appears cross-resistant with radiotherapy and/or platinum-based cytotoxic therapy in heavily pretreated patients with squamous carcinoma of the cervix.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

A V Hallum, and D S Alberts, and S M Lippman, and L Inclan, and G J Shamdas, and J M Childers, and E A Surwit, and M Modiano, and K D Hatch
13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix.
March 1993, Journal of the National Cancer Institute,
A V Hallum, and D S Alberts, and S M Lippman, and L Inclan, and G J Shamdas, and J M Childers, and E A Surwit, and M Modiano, and K D Hatch
13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix.
February 1992, Journal of the National Cancer Institute,
A V Hallum, and D S Alberts, and S M Lippman, and L Inclan, and G J Shamdas, and J M Childers, and E A Surwit, and M Modiano, and K D Hatch
13-Cis-retinoic acid plus interferon-alpha 2a in recurrent respiratory papillomatosis.
June 1994, Journal of the National Cancer Institute,
A V Hallum, and D S Alberts, and S M Lippman, and L Inclan, and G J Shamdas, and J M Childers, and E A Surwit, and M Modiano, and K D Hatch
Unexpected radiation protection with 13-cis-retinoic acid plus interferon alpha-2a.
January 1994, Cancer chemotherapy and pharmacology,
A V Hallum, and D S Alberts, and S M Lippman, and L Inclan, and G J Shamdas, and J M Childers, and E A Surwit, and M Modiano, and K D Hatch
Phase II study of 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer.
February 1993, Anti-cancer drugs,
A V Hallum, and D S Alberts, and S M Lippman, and L Inclan, and G J Shamdas, and J M Childers, and E A Surwit, and M Modiano, and K D Hatch
Low activity of 13-cis-retinoic acid plus interferon alpha 2a in advanced renal cell carcinoma.
April 2002, American journal of clinical oncology,
A V Hallum, and D S Alberts, and S M Lippman, and L Inclan, and G J Shamdas, and J M Childers, and E A Surwit, and M Modiano, and K D Hatch
[13-cis retinoic acid and interferon-alfa-2a as palliative therapy in pretreated, recurrent squamous epithelial carcinoma of the cervix uteri and vulva].
October 1996, Geburtshilfe und Frauenheilkunde,
A V Hallum, and D S Alberts, and S M Lippman, and L Inclan, and G J Shamdas, and J M Childers, and E A Surwit, and M Modiano, and K D Hatch
A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893).
January 2003, Cancer investigation,
A V Hallum, and D S Alberts, and S M Lippman, and L Inclan, and G J Shamdas, and J M Childers, and E A Surwit, and M Modiano, and K D Hatch
13-cis-retinoic acid plus interferon-alpha: a phase II clinical study in squamous cell carcinoma of the lung and the head and neck.
January 1994, Oncology,
A V Hallum, and D S Alberts, and S M Lippman, and L Inclan, and G J Shamdas, and J M Childers, and E A Surwit, and M Modiano, and K D Hatch
Interferon-alpha 2a, 13-cis-retinoic acid and radiotherapy for locally advanced carcinoma of the cervix: a pilot study.
January 1998, European journal of gynaecological oncology,
Copied contents to your clipboard!